Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An IOM Report on Redefining an Illness
JAMA 313:1101-1102, Clayton, E.W., 2015
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon
Practical Neurology 7:16-23, Christensen,D.B., 2008
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Immunologic Treatment of Alzheimer's Disease
NEJM 341:1694-1695, Blass,J.P., 1999
The Genetics of Alzheimer Disease, Current Status and Future Prospects
Arch Neurol 55:294-296, Blacker,D.&Tanzi,R.E., 1998
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
Complete Genomic Screen in Late-Onset Familial Alzheimer Disease, Evidence for a New Locus on Chromosome 12
JAMA 278:1237-1241, 12821997., Pericak-Vance,M.A.,et al, 1997
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997